Colonial River Investments LLC Takes Position in Sanofi (NASDAQ:SNY)

Colonial River Investments LLC purchased a new position in shares of Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 5,997 shares of the company's stock, valued at approximately $333,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Cardinal Capital Management lifted its stake in shares of Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after acquiring an additional 199 shares during the last quarter. Gradient Investments LLC grew its holdings in shares of Sanofi by 2.1% in the first quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock worth $542,000 after purchasing an additional 200 shares during the last quarter. Providence Capital Advisors LLC increased its stake in shares of Sanofi by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after buying an additional 201 shares during the period. Perigon Wealth Management LLC raised its holdings in Sanofi by 3.1% during the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock valued at $367,000 after buying an additional 201 shares during the last quarter. Finally, Bailard Inc. boosted its position in Sanofi by 1.4% during the 4th quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after buying an additional 220 shares during the period. Hedge funds and other institutional investors own 14.04% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SNY. Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Stock Up 0.5%

Shares of NASDAQ SNY traded up $0.26 during mid-day trading on Wednesday, hitting $49.31. 1,776,233 shares of the stock traded hands, compared to its average volume of 2,342,439. The company has a market cap of $120.93 billion, a price-to-earnings ratio of 17.61, a PEG ratio of 0.99 and a beta of 0.49. The stock has a fifty day moving average price of $50.84 and a 200-day moving average price of $52.05. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The firm had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. The company's revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.78 EPS. Research analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were issued a $2.0369 dividend. The ex-dividend date was Friday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's payout ratio is 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.